Intelligence Platform
Clinical trials, SEC filings,
hedge fund positioning,
and how they connect.
One database, organized by company, updated daily from primary sources. Built for BD, investors, and strategy teams.
$499/mo
Cancel anytime. Access continues through the end of the billing period.
Live Platform Data
On the platform right now, from primary sources.
Updated Aug 30, 2026
Endpoint modifications, enrollment shifts, and status changes detected automatically for every registered trial.
The primary endpoints for mean and median calculated annualized bleed rate for treated bleeds had their timeframes extended from at least 52 weeks to a median of 156.07 weeks (up to 274 weeks). Additionally, several secondary endpoints related to annualized bleed rates were added, specifically focusing on 'Long-term Efficacy' with extended timeframes. The timeframes for many CATCH questionnaire and safety-related secondary endpoints were also extended, generally from approximately 48 months to approximately 274 weeks. Some secondary endpoints were removed, such as 'Change From Baseline in Body Temperature Over Time', 'Change From Baseline in Diastolic Blood Pressure Over Time', 'Change From Baseline in Pulse Rate Over Time', and 'Change From Baseline in Respiratory Rate Over Time'. New secondary endpoints were added, including 'Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs' and 'Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4'.
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Number Of Arms: 11 → 13
Hedge fund ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.
SPHERA FUNDS MANAGEMENT LTD.
Stonepine Capital Management, LLC
RTW INVESTMENTS, LP
8-K filings classified by type: licensing deals, FDA actions, financing events, and strategic reviews, identified automatically.
PTC Therapeutics, Inc. has entered into an asset purchase agreement to acquire ST-920, a one-time administered AAV gene therapy product candidate for Fabry disease, from Sangamo Therapeutics, Inc. for an upfront payment of $111 million. The agreement also includes up to $100 million in contingent milestone payments tied to accelerated and full FDA approval of a BLA for ST-920 based on Sangamo's Phase 1/2 STAAR study. This acquisition follows PTC being selected as the winning bidder in Sangamo's bankruptcy auction.
Gossamer Bio, Inc. secured a private placement agreement to raise up to $250 million, with an initial $25.0 million closing. Additional funds of $125.0 million are contingent on FDA acceptance of the NDA for seralutinib in pulmonary arterial hypertension (PAH) by 2026, and a further $100.0 million from warrants upon FDA approval. Proceeds will support the clinical development and potential commercialization of seralutinib for PAH and PH-ILD.
Genprex, Inc. announced a strategic development and manufacturing agreement with a leading U.S. based CDMO to scale up production of its diabetes gene therapy program. This collaboration will transition the AAV-based therapeutic candidate, designed for Type 1 and Type 2 diabetes, from research-grade to cGMP-compliant clinical and commercial-ready output. The CDMO will supply drug product for IND-enabling preclinical studies and future clinical trials.
All items link to original SEC documents and registry records on the platform.
Data
Primary sources, all linked.
Every data point traces to the original filing or registry record. No news, no analyst commentary, no third-party data vendors.
ClinicalTrials.gov
450K+ trials. Status, enrollment, endpoints, results, and change tracking. Updated daily.
SEC EDGAR
8-K, 10-K, 10-Q, Form 4, 13D/13G, 13F and more. Parsed and classified. Updated multiple times daily.
Financial Data
Filter companies by market cap, cash, expenses, and more for 500+ biotech companies.
FDA Data
Drug products, patent listings, and exclusivity records. Integrated
app.rxdatalab.com
What you can do
Built for BD, investors, and strategy teams who work from primary sources rather than news and analyst commentary.
Track a company across every source
Trial pipeline, 8-Ks, Regulatory filings, and financials in one view. Every item links to the original source document or registry record.
Monitor trial changes automatically
Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Nothing buried in the registry.
See who's building positions in biotech
Fund profiles with full position history and filing records. Multi-fund convergence on the same company. 13D/G cross-referenced with 8-K events and trial milestones.
See live data sample →Search SEC filings by what they mean
8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or filing type, not just keyword.
See live data sample →Map competitive landscapes
Search by indication and surface every company running trials for that indication or related indications. Overlay financial position and recent trial events across the competitive field.
Organize research with projects and notes
Create projects with company and trial watchlists. Add timestamped notes directly on company and trial pages. Dashboard shows what changed across your coverage since your last session.
Data In Context
Every event, in context.
Financing events, licensing deals, trial changes, and hedge fund moves — overlaid on the quarterly financial timeline for Solid Biosciences Inc. (SLDB). Toggle layers, hover annotations, click any event to see the original source.
Competitive Landscape
Explore the competitive biotech landscape.
Search any indication. We map every industry trial using the NLM's MeSH medical ontology, then overlays institutional ownership, financial position, and recent trial events across the competitive field.
Condition Landscape
Active industry trials per condition. Search any condition on the platform.
Active Sponsors
| Company | Mkt Cap | Trials | Cash | Qtr Exp |
|---|---|---|---|---|
| Legend Biotech Corp LEGN | $3.9B | 1 | — | — |
| Cullinan Therapeutics, Inc. CGEM | $1.3B | 1 | $79M | $57M |
| Autolus Therapeutics plc AUTL | $623M | 1 | $171M | $69M |
| C4 Therapeutics, Inc. CCCC | $474M | 3 | $79M | $33M |
| Caribou Biosciences, Inc. CRBU | $174M | 2 | $26M | $27M |
| Karyopharm Therapeutics Inc. KPTI | $42M | 2 | $55M | $55M |
| Cellectar Biosciences, Inc. CLRB | $24M | 1 | $34M | $7M |
| Senti Biosciences, Inc. SNTI | $12M | 1 | $8M | $14M |
Sample data. Financial data from parsed 10-K/Q filings. Qtr Exp = R&D + G&A per quarter.
Trial monitoring
Trials can quietly change, don't miss it
Daily comparison against ClinicalTrials.gov. Every endpoint modification, enrollment shift, and status change categorized and summarized automatically.
NCT04158648
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Roche Holding Ltd RHHBY
Enrollment
73
Primary Completion
2021-10
Detected
Aug 28, 2026
Secondary endpoint 1 timeframe
+ 1 more change detected
AI Summary
The primary endpoints for mean and median calculated annualized bleed rate for treated bleeds had their timeframes extended from at least 52 weeks to a median of 156.07 weeks (up to 274 weeks). Additionally, several secondary endpoints related to annualized bleed rates were added, specifically focusing on 'Long-term Efficacy' with extended timeframes. The timeframes for many CATCH questionnaire and safety-related secondary endpoints were also extended, generally from approximately 48 months to approximately 274 weeks. Some secondary endpoints were removed, such as 'Change From Baseline in Body Temperature Over Time', 'Change From Baseline in Diastolic Blood Pressure Over Time', 'Change From Baseline in Pulse Rate Over Time', and 'Change From Baseline in Respiratory Rate Over Time'. New secondary endpoints were added, including 'Number of Participants With at Least One Adverse Events of Changes From Baseline in Vital Signs' and 'Number of Participants With at Least One Shifts in Clinical Laboratory Parameters From Baseline WHO Toxicity Scale Grade 0-2 to Post-baseline Grade 3 or 4'.
Full change history per trial. Every detection timestamped and linked to the original registry record.
Subscribe to access →Pricing
Simple, transparent pricing.
Individual — Monthly
Billed monthly. Cancel anytime from your account page.
- ✓ Full platform access
- ✓ BioHedge (13D/G fund positioning)
- ✓ Clinical trial change detection
- ✓ 8-K signal detection
- ✓ Competitive landscape mapping
- ✓ Research workspace and notes
Teams & Institutions
Custom pricing
For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.
- ✓ Multi-seat access
- ✓ Custom data coverage and exports
- ✓ Invoiced billing and enterprise contracts
- ✓ API access and custom data feeds
- ✓ Dedicated support
What happens after payment?
You'll receive a welcome email with a link to set your password. Access immediately once your password is set.
How do I cancel?
Go to your account page and click "Manage Billing." Access continues through the end of your billing period.
Do you offer trials or demos?
The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.
Questions or enterprise pricing?
Email [email protected] for team access, institutional pricing, or anything else.
By subscribing you agree to our Terms of Service and Data License Agreement.